Novartis AG (NOVN) Given a CHF 91 Price Target at Societe Generale

Novartis AG (VTX:NOVN) has been given a CHF 91 price target by research analysts at Societe Generale in a research report issued on Wednesday, July 19th. The firm currently has a “buy” rating on the stock.

Receive News & Ratings for Novartis AG Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Several other equities analysts have also commented on NOVN. J P Morgan Chase & Co set a CHF 70 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Saturday, May 20th. Jefferies Group LLC set a CHF 100 price target on shares of Novartis AG and gave the stock a “buy” rating in a research report on Saturday, May 20th. Morgan Stanley set a CHF 75 price target on shares of Novartis AG and gave the stock a “sell” rating in a research report on Saturday, May 20th. Finally, Barclays PLC set a CHF 65 price target on shares of Novartis AG and gave the stock a “sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company’s stock. Novartis AG has a consensus rating of “Hold” and a consensus price target of CHF 84.60.

Shares of Novartis AG (NOVN) opened at 82.60 on Wednesday. The stock has a 50 day moving average of CHK 80.43 and a 200 day moving average of CHK 76.91. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35.

ILLEGAL ACTIVITY WARNING: This news story was reported by [[site]] and is the sole property of of [[site]]. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at [[permalink]].

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.